Treatment Patterns of Neratinib in HER2+ EBC in China

A Multicenter, Open-label, Single-arm, Non-interventional Study to Investigate the Treatment Patterns of Nerlynx® (Neratinib) in HER2-positive Early-stage Breast Cancer in China

This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China

Inclusion Criteria:

• Signed written informed consent approved by the reviewing Ethics Committee (EC).
• Adult patients (≥18 years of age, no upper limit).
• Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or metastatic disease.

Exclusion Criteria:

• Presence of any contraindication with regard to the neratinib treatment.
• Current or upcoming participation in an interventional clinical trial. (Investigational treatment within four weeks of enrolment).